ライフサイエンスコーパス: vertebral fracture

1 al spine radiographs were used to assess for vertebral fracture.

2 9% in women with normal BMD and no prevalent vertebral fracture.

3 based on prevalent radiographically defined vertebral fracture.

4 (a T score of less than -2.5), and 61% had a vertebral fracture.

5 ) analyses were used to assess predictors of vertebral fracture.

6 in HRQOL associated with subsequent incident vertebral fracture.

7 acture during the year following an incident vertebral fracture.

8 dent nonvertebral fracture, hip fracture, or vertebral fracture.

9 e spine and femoral neck and reduces risk of vertebral fracture.

10 g globulin have an increased risk of hip and vertebral fracture.

11 duced risk for hip fracture but not wrist or vertebral fracture.

12 based on presence or absence of an existing vertebral fracture.

13 one patient with alendronate developed a new vertebral fracture.

14 the control patients sustained at least one vertebral fracture.

15 The primary end point was new vertebral fracture.

16 e most affected by hyperkyphosis do not have vertebral fractures.

17 ertebral and symptomatic vertebral), and non-vertebral fractures.

18 tly reduced the risk of new or worsening SQ3 vertebral fractures.

19 ich decrease the probability of pathological vertebral fractures.

20 idism, are at increased risk for new hip and vertebral fractures.

21 but not DXA, is an independent predictor of vertebral fractures.

22 ntion of bone loss and complications such as vertebral fractures.

23 region to region than does the prevalence of vertebral fractures.

24 The primary outcome was new radiographic vertebral fractures.

25 asured by QCT was a significant predictor of vertebral fractures.

26 erformed on all subjects to assess prevalent vertebral fractures.

27 were significantly associated with prevalent vertebral fractures.

28 aratide reduces the risk of nonvertebral and vertebral fractures.

29 ad low bone mineral density and/or prevalent vertebral fractures.

30 falls, clinical fractures, and radiographic vertebral fractures.

31 te treatment had the lowest incidence of new vertebral fractures.

32 and again at 36 or 48 months to identify new vertebral fractures.

33 included proximal femur BMD and incidence of vertebral fractures.

34 risk have not been studied for women without vertebral fractures.

35 in BMD are associated with lower risk of new vertebral fractures.

36 s of bone turnover, and the incidence of new vertebral fractures.

37 e not significantly associated with wrist or vertebral fractures.

38 rongly associated with both trochanteric and vertebral fractures.

39 itamin D might influence the risk of hip and vertebral fractures.

40 of bone mineral density and higher risk for vertebral fractures.

41 vent radiographically defined (morphometric) vertebral fractures.

42 in placebo-controlled trials to reduce only vertebral fractures.

43 al CT images assessed for moderate-to-severe vertebral fractures.

44 were analyzed for association with incident vertebral fractures.

45 tently distinguish children with and without vertebral fractures.

46 one, raloxifene, and estrogen reduce primary vertebral fractures.

47 osteoporosis and the extent and severity of vertebral fractures.

48 es at 36 months, as well as incidence of new vertebral fractures.

49 e recorded a significant reduction of 34% in vertebral fractures (0.66, 0.59-0.73), but only a small

50 0.59-0.73), but only a small effect for non-vertebral fractures (0.93, 0.87-0.99).

51 but no significant reduction in morphometric vertebral fractures (11.3% for placebo and 9.8% for alen

52 ts with baseline and 1-year followup data on vertebral fractures (111 receiving placebo and 195 recei

53 lacebo, was associated with reduced risks of vertebral fracture (13.1 cases vs. 22.4 cases per 1000 p

54 lacebo, was associated with reduced risks of vertebral fracture (16.0 vs. 22.4 cases per 1000 person-

55 In women with low BMD but without vertebral fractures, 4 years of alendronate safely incre

56 or less (Hologic Inc, Waltham, Mass) but no vertebral fracture; 4432 were randomized to alendronate

57 ficantly lower risk of clinically recognized vertebral fractures (5.3% for placebo and 2.4% for alend

58 ted in patients with severe osteoporosis and vertebral fractures (54%), as compared with controls (27

59 patients with at least 1 moderate-to-severe vertebral fracture, 62 (52.1%) had nonosteoporotic T-sco

60 Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard ratio, 0.6

61 confidence interval, 1.1 to 3.9) and 2.3 for vertebral fracture (95 percent confidence interval, 1.2

62 fidence interval, 1.4 to 4.6) and subsequent vertebral fracture (95 percent confidence interval, 1.4

63 onfidence interval, 1.5 to 32.0) and 7.9 for vertebral fracture (95 percent confidence interval, 2.2

64 Risk of vertebral fracture after IG-IMRT for spinal metastases h

65 Children with ALL have a high incidence of vertebral fractures after 12 months of chemotherapy, and

66 New vertebral fractures after PVP were clustered within pati

67 were two times as likely to have one or more vertebral fractures: age-adjusted odds ratio (OR) = 1.80

68 ship existed between inhaled steroid use and vertebral fractures: age-adjusted OR = 1.35; 95% CI, 0.7

69 between continuous systemic steroid use and vertebral fractures: age-adjusted OR = 2.36; 95% CI, 1.2

70 among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and s

71 fracture at baseline, those with an incident vertebral fracture also had a greater risk for increased

72 rteen (52%) of the 25 children with incident vertebral fractures also had fractures at baseline.

73 Women with any prevalent vertebral fractures also had increased mortality risk fr

74 ociated with a significantly reduced risk of vertebral fracture among men with osteoporosis.

75 e hip and the spine and reduces the risk for vertebral fractures among individuals with CKD.

76 ites and a reduction in the incidence of new vertebral fractures among men receiving androgen-depriva

77 men with at least two moderate or one severe vertebral fracture and a bone mineral density T score of

78 and matched pair analyses were performed on vertebral fracture and patient levels.

79 lative risk reductions from 0.40 to 0.60 for vertebral fractures and 0.60 to 0.80 for nonvertebral fr

80 -body bone mineral density and helps prevent vertebral fractures and decreases in height.

81 Incident hip and clinical vertebral fractures and initiation of treatment with bis

82 months of chemotherapy, and the presence of vertebral fractures and reductions in spine BMD Z-scores

83 e and safe procedure for patients with acute vertebral fractures and will help to inform decisions re

84 n with new hip fractures, 149 women with new vertebral fractures, and a subsample of 398 women random

85 reater increase in spine BMD, a reduction in vertebral fractures, and no effect on nonvertebral fract

86 bone density, moderate and severe prevalent vertebral fractures, and number of prevalent vertebral f

87 oking, spine bone mineral density, number of vertebral fractures, and severe vertebral fractures (rel

88 e on the prevalence of osteoporosis, risk of vertebral fractures, and the recent advances in the trea

89 Our data indicate that women who develop a vertebral fracture are at substantial risk for additiona

90 Osteoporosis and vertebral fractures are a consequence of glucocorticoid

91 Vertebral fractures are a hallmark of postmenopausal ost

92 These data indicate that vertebral fractures are common in older men with COPD; t

93 Low BMD and prevalent vertebral fractures are independently related to new ver

94 men and those with two or more radiographic vertebral fractures are needed.

95 Vertebral fractures are the most common osteoporotic fra

96 with bone-mineral density at other sites and vertebral fractures as secondary endpoints.

97 utcomes included new vertebral, hip, and non-vertebral fractures as well as bone mineral density (BMD

98 s the frequency of morphometric and clinical vertebral fractures, as well as other clinical fractures

99 here was 1.8-fold increased odds of incident vertebral fracture at 12 months (95% CI, 1.2 to 2.7; P =

100 points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incid

101 324 of the 2286 (14.2%) without a prevalent vertebral fracture at baseline (odds ratio, 4.21; 95% co

102 ding 163 of the 394 (41.4%) with a prevalent vertebral fracture at baseline and 324 of the 2286 (14.2

103 Results for women with at least one vertebral fracture at baseline are reported here.

104 Among women without a vertebral fracture at baseline, those with at least one

105 donors with from those without osteoporotic vertebral fractures at 3.0 T than at 1.5 T.

106 d denosumab had a decreased incidence of new vertebral fractures at 36 months (1.5%, vs. 3.9% with pl

107 the incidence in subjects without prevalent vertebral fractures at baseline (relative risk [RR], 5.1

108 Presence of 1 or more vertebral fractures at baseline increased risk of sustai

109 Vertebral fractures at baseline increased the odds of an

110 ensity (BMD), back pain, and the presence of vertebral fractures at baseline were analyzed for associ

111 Prevalent radiographic vertebral fractures at baseline were defined by morphome

112 nical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis

113 Denosumab also reduces risk for radiographic vertebral fractures, based on 1 trial.

114 ab reduce the risk of hip, nonvertebral, and vertebral fractures; bisphosphonates are commonly used a

115 Raloxifene may prevent vertebral fractures but may not improve BMD (low SOE).

116 bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compli

117 hormone reduced the risk for new or worsened vertebral fractures, but in sensitivity analyses, the ma

118 acture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk ha

119 s at baseline increased risk of sustaining a vertebral fracture by 5-fold during the initial year of

120 dronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as com

121 s assessed at the lumbar spine and femur and vertebral fracture by morphometric X-ray absorptiometry.

122 o, decreased the cumulative incidence of new vertebral fractures by 41 % (95% confidence interval [CI

123 endronate decreased the risk of radiographic vertebral fractures by 44% overall (relative risk, 0.56;

124 with cystic fibrosis (CF), rib and thoracic vertebral fractures can have adverse effects on lung hea

125 ts in this rare case of traumatic complex C2 vertebral fracture caused by a gunshot injury.

126 comes included new and worsened radiographic vertebral fractures, clinical fractures (a composite of

127 onate group had one or more new morphometric vertebral fractures compared with 145 (15.0%) in the pla

128 higher fracture risk other than for clinical vertebral fractures compared with those who continued al

129 l mass was associated with a reduced rate of vertebral fracture, despite increased bone turnover.

130 The incidence of vertebral fractures did not differ significantly among t

131 bral hemangioma, in another 4 - pathological vertebral fractures due to metastases, and in one case -

132 Vertebral fractures due to osteoporosis are a potential

133 Occurrence of radiographically identified vertebral fracture during the year following an incident

134 To date, the incidence of vertebral fractures during ALL treatment has not been re

135 first 12 months had a lower incidence of new vertebral fractures during the entire followup period.

136 iated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary

137 Primary end points were vertebral fractures, estrogen receptor (ER)-positive bre

138 New vertebral fractures, even those not recognized clinicall

139 evealed that the risks of diabetes mellitus, vertebral fractures, femoral neck fractures, and hip fra

140 The corresponding percentages of vertebral fractures for DXA and quantitative CT with a 5

141 Three- and 12-month vertebral fracture-free probability was 97.0% and 94.5%,

142 al parameters in differentiating donors with vertebral fractures from those without was assessed by u

143 ally significant, while interactions between vertebral fracture grade and the other variables were no

144 The effect of baseline vertebral fracture grade on baseline HRQOL was statistic

145 re modeled as a function of maximum baseline vertebral fracture grade, while controlling for age, bon

146 combinant human parathyroid hormone 1-34) on vertebral fracture grades that most strongly impact HRQO

147 n in analyses of the combined wrist, hip, or vertebral fracture group (n = 92).

148 At baseline, women with a prevalent vertebral fracture had significantly lower OPAQ scores o

149 to demonstrate that osteoporotic women with vertebral fractures had lost substantially more bone fro

150 ctures in the period immediately following a vertebral fracture has not been evaluated.

151 A reduction in vertebral fractures has consistently been seen across al

152 Women with a prevalent vertebral fracture have a substantially increased absolu

153 low bone mineral density (BMD) and prevalent vertebral fractures have a greater risk of incident vert

154 In older women with vertebral fractures, hyperkyphosis predicts an increased

155 Mean Outcome Measure Incident vertebral fractures identified from lateral spinal radio

156 2.97 (95% confidence interval 1.63-9.56) for vertebral fracture in individuals who carry the 's' alle

157 with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized

158 C dose was found to be a strong predictor of vertebral fracture in patients receiving GCs.

159 reduced the overall risk for new or worsened vertebral fracture in postmenopausal women with osteopor

160 Predictors of vertebral fracture in the placebo group were identified

161 t vertebral fracture, the incidence of a new vertebral fracture in the subsequent year was 19.2% (95%

162 nd reduced the incidence of new radiographic vertebral fractures in 1 high-quality trial.

163 ated the association between steroid use and vertebral fractures in 312 men, 50 yr of age or older, w

164 or any clinical fracture, hip fractures, and vertebral fractures in men with prostate cancer.

165 Suspecting and promptly recognizing vertebral fractures in patients with AS could prevent se

166 There were proportionally fewer new vertebral fractures in the alendronate groups (overall i

167 The cumulative incidence of new vertebral fractures in the first year was 6.6%.

168 isk of future fractures, but risk of further vertebral fractures in the period immediately following

169 or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis

170 Primary end points were new vertebral fracture (in patients not taking concomitant o

171 the 2680 women, 487 (18.2%) had an incident vertebral fracture including 163 of the 394 (41.4%) with

172 in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving p

173 Low bone density and the occurrence of vertebral fractures indicate that cardiac, renal, and bo

174 dy examined whether radiographically defined vertebral fracture is a risk factor for mortality in old

175 Vertebral fracture is common after single fraction IG-IM

176 A single radiographic vertebral fracture is not a risk for mortality in older

177 at the prevalence of osteoporosis is 25% and vertebral fractures is 10% in patients with AS.

178 The prevalence of morphometric vertebral fractures is higher in patients with IBD than

179 However, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 y

180 yroid hormone (1-34), and raloxifene prevent vertebral fractures more than placebo; the evidence for

181 ed to compare the prevalence of morphometric vertebral fractures (MVF) between patients with inflamma

182 , lumbar facet syndrome, painful compressive vertebral fractures, myofascial pain and postlaminectomy

183 treatment was not associated with prevalent vertebral fractures nor with taking corticosteroids (r =

184 th inflammatory conditions demonstrated that vertebral fractures occur in a significant minority of p

185 lure, RRT, all fractures, hip fractures, and vertebral fractures occurred in 0.6%, 0.2%, 0.7%, 0.1%,

186 New vertebral fractures occurred in 14 percent of the women

187 f 19 months of therapy, new or worsening SQ3 vertebral fractures occurred in 21 of 448 patients (4.7%

188 At 24 months, new vertebral fractures occurred in 28 (5.4%) of 680 patient

189 Fewer new vertebral fractures occurred in the teriparatide group t

190 In addition, 24 (67%) of the 36 new vertebral fractures occurred within 30 days after treatm

191 ssociated with an increased risk of incident vertebral fracture (odds ratio per 1 SD decrease in tota

192 to 12.9]) and a fourfold increased risk for vertebral fracture (odds ratio, 4.5 [CI, 1.3 to 15.6]) c

193 ting in an absolute risk reduction for a new vertebral fracture of 14%.

194 % CI, 11% to 23%) had a total of 61 incident vertebral fractures, of which 32 (52%) were moderate or

195 cations such as long-term steroid therapy or vertebral fractures on radiography, do not get screened

196 2.49) and with no history of hip or clinical vertebral fracture or of treatment for osteoporosis, fol

197 r the short-term, but their absolute risk of vertebral fracture over the long-term is uncertain.

198 l fractures are independently related to new vertebral fractures over 15 years of follow-up.

199 rticipants with one or more new morphometric vertebral fractures over a period of 24 months.

200 al fractures have a greater risk of incident vertebral fractures over the short-term, but their absol

201 zoledronic acid had fewer moderate-to-severe vertebral fractures (P=0.03) and less height loss (P=0.0

202 Vertebral fracture prevalence, as determined by morphome

203 New or worsened vertebral fractures (primary outcome) and changes in bon

204 be an important marker for low bone mass and vertebral fracture, raising the possibility that genotyp

205 The absolute risk of vertebral fracture ranged from 56% among women with tota

206 ctures (ranging from 0.90% to 1.86%) and non-vertebral fractures (ranging from 0.84% to 2.55%) remain

207 The yearly incidence of new vertebral fractures (ranging from 0.90% to 1.86%) and no

208 osteoporotic range and/or preexisting hip or vertebral fracture reduce fracture risk.

209 lth-related quality of life, 1-year clinical vertebral fracture reduction, and the correlation of bon

210 nd biochemical markers of bone turnover with vertebral fracture reduction.

211 y, number of vertebral fractures, and severe vertebral fractures (relative hazard per SD increase, 1.

212 Rates of vertebral fractures (relative risk, 1.45; 95% CI, 1.19 t

213 risk for osteoporosis and women with occult vertebral fractures remains a clinical challenge.

214 eductions of 42% and 33% in risk for hip and vertebral fractures, respectively, compared with inactiv

215 ronic lung disease, the relationship between vertebral fracture risk and BMD is similar to that seen

216 ams, making roentgenography a novel tool for vertebral fracture risk assessment in the future.

217 ne density as the most reliable parameter in vertebral fracture risk assessment.

218 rolled trial that assessed vertebral and non-vertebral fracture risk reduction in women, trials in me

219 also increased in the presence of prevalent vertebral fractures (RR, 9.3; 95% CI, 1.2-71.6; P =.03).

220 The association between vertebral fracture severity and health-related quality o

221 Vertebral fracture severity was assessed by the visual s

222 We sought to determine whether vertebral fracture severity was associated with HRQOL sc

223 cing the risks of invasive breast cancer and vertebral fracture should be weighed against the increas

224 Prevention of new vertebral fractures should reduce the burden of back pai

225 Incident vertebral fractures significantly decreased OPAQ scores

226 Vertebral fractures significantly increase lifetime risk

227 n randomized to a placebo group and for whom vertebral fracture status was known at entry (n = 2725).

228 d bone marrow composition as determinants of vertebral fracture status were examined.

229 On stratification by prevalent vertebral fracture status, only women with prevalent fra

230 ion, which, with BMD, improves prediction of vertebral fracture status.

231 er patients in the zoledronic acid group had vertebral fractures than did those in the clodronic acid

232 New vertebral fractures that did not come to medical attenti

233 e 381 participants who developed an incident vertebral fracture, the incidence of a new vertebral fra

234 For clinically apparent vertebral fractures, the corresponding numbers were 23 (

235 At the time of diagnosis of the vertebral fractures, the patients' ages ranged from 10.6

236 New vertebral fractures, the primary endpoint, were defined

237 BMD T score of -2.5 or less and a prevalent vertebral fracture to 9% in women with normal BMD and no

238 ting postmenopausal women who have prevalent vertebral fractures to prevent further decreases in HRQO

239 ssigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parath

240 of -2.0 or less and radiologic evidence of a vertebral fracture, to receive once-daily tibolone (at a

241 of 64 in the control group) and symptomatic vertebral fracture (two and three, respectively).

242 eoporosis who were suspected of having acute vertebral fracture underwent DE CT and MR imaging.

243 Vertebral bodies were assessed for incident vertebral fractures using the Genant semiquantitative me

244 The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group

245 The risk ratio for thoracolumbar vertebral fracture was 2.2 (95% CI, 0.9-5.5).

246 The effect of prevalent vertebral fracture was dependent on the location within

247 The incidence of vertebral fracture was determined morphometrically by us

248 Incident vertebral fracture was determined radiographically at ba

249 Prevalent vertebral fracture was not associated with all-cause mor

250 trend toward a decrease in the incidence of vertebral fracture was observed in the 5-mg risedronate

251 Frequency of vertebral fracture was reduced both in women who did and

252 The risk of developing a new or worsened SQ3 vertebral fracture was reduced by 86% (P < 0.001) in pat

253 Risk of vertebral fracture was reduced in both study groups rece

254 The presence of vertebral fracture was related to BMD at the femoral nec

255 The prevalence of one or more vertebral fractures was 48.7% in the NSU group, 57.1% in

256 The incidence of vertebral fractures was lower in the alendronate group t

257 period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-a

258 001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the

259 t baseline, those with at least one incident vertebral fracture were more likely to have increased ba

260 Prevalent and incident radiographic vertebral fractures were assessed by quantitative morpho

261 SQ grade 3 (SQ3) vertebral fractures were associated with a significantly

262 Both prevalent and incident radiographic vertebral fractures were associated with decreased HRQOL

263 prevalent fractures of lesser severity, SQ3 vertebral fractures were associated with reduced HRQOL.

264 New symptomatic vertebral fractures were based on self-report and confir

265 Prevalent and incident vertebral fractures were detected by vertebral morphomet

266 Adults with one to three acute vertebral fractures were eligible for enrolment in this

267 Prevalent vertebral fractures were identified on the baseline radi

268 Vertebral fractures were measured by radiography at base

269 Vertebral fractures were present in 19% of subjects and

270 fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, r

271 Non-vertebral fractures were reported in 292 individuals, 15

272 two consecutive patients with 37 morphologic vertebral fractures were studied between October 2015 an

273 ctures) and 10 control examinations (without vertebral fractures), were performed.

274 of > or =3% in total hip BMD experienced new vertebral fractures, whereas twice as many women (6.3%)

275 es have not controlled for clinically silent vertebral fractures, which are a known mortality risk fa

276 asive procedure for the treatment of painful vertebral fractures, which is intended to reduce pain an

277 s associated with a reduction in the rate of vertebral fractures, which was significant when fracture

278 Treatment of vertebral fractures with percutaneous PMMA vertebroplast

279 fractures and 138 women who subsequently had vertebral fractures with those in randomly selected cont

280 h the placebo group, had a decreased risk of vertebral fracture, with 70 cases versus 126 cases per 1

281 nosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3%

282 osteoporosis before having a hip or clinical vertebral fracture, with adjustment for estrogen use and

283 .4 to 175 g and was strongly associated with vertebral fracture, with the odds ratio between the high

284 vertebral fractures, and number of prevalent vertebral fractures, women with greater kyphosis were at